ABX300, a Centyrin-KRAS siRNA Conjugate for KRAS Mutant Tumors

Time: 1:30 pm


  • The unique biochemical and biophysical properties of Centyrins enable functional
    delivery of siRNA payloads in receptor positive cells
  • Dual antigen targeting with bispecific Centyrins can improve access to target cell types
  • EpCAM-CD71 Centyrin-KRAS siRNA conjugates induce RNAi in G12C and other
    KRAS mutant tumor cells